Chronic Hydralazine Use Linked to Multiorgan Failure
A new case study detailed how a 71-year-old man developed severe autoimmune complications from blood pressure medication.
Updated on Oct. 1, 2026 in Heart Disease
A medical case study published on August 18, 2026, documented a 71-year-old patient who developed multiorgan failure after four months of hydralazine therapy. Physicians attributed the condition to a rare hydralazine-induced autoimmune syndrome.
Why it matters
This case highlights the risks of chronic hydralazine use, which can trigger an overlapping syndrome of ANCA-associated vasculitis and drug-induced lupus erythematosus. Understanding these potential side effects is essential for clinicians monitoring patients on long-term hypertension regimens.
A 71-year-old patient presented with severe symptoms after a four-month regimen of 75 mg of hydralazine taken three times daily. Medical staff performed a pericardiocentesis to remove 650 mL of fluid and administered 120 mg of intravenous furosemide.
The players
JACC: Case Reports
This is a peer-reviewed medical journal published by the American College of Cardiology that focuses on clinical case studies and medical education.
The details
The patient, who had a history of chronic myelomonocytic leukemia and kidney disease, experienced three weeks of gastrointestinal distress before being hospitalized. Clinical testing revealed positive antinuclear, ANCA, and antihistone antibodies, confirming the diagnosis of hydralazine-induced autoimmune syndrome.
Timeline
The patient began taking 75 mg of hydralazine three times daily four months before his hospitalization.
The patient experienced abdominal pain, diarrhea, and vomiting for three weeks prior to admission.
On day 17 of his hospitalization, the patient suffered respiratory failure, bradycardia, and acute kidney injury.
The clinical case study was published in JACC: Case Reports on August 18, 2026.
The Big Picture
This case study updates clinical understandings of drug-induced autoimmunity established by prior reports. The findings follow a growing pattern of reported autoimmune complications associated with long-term hydralazine exposure.
Patients prescribed hydralazine for hypertension should maintain regular communication with their healthcare providers regarding new or persistent symptoms. Reporting signs such as unexplained abdominal pain or difficulty breathing can assist doctors in early detection of potential adverse reactions.
The takeaway
This case serves as a critical reminder for patients and providers to monitor for signs of autoimmune illness during long-term medication use. Prompt discontinuation of hydralazine is often the primary step in managing drug-induced complications when symptoms arise.
Further reading
For more information on cardiovascular health, visit the Heart Disease section.
More information
View the original JACC: Case Reports clinical study for detailed medical analysis.
Source note: This article includes information reported by Renal and Urology News.
